Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S253000
Reexamination Certificate
active
07902204
ABSTRACT:
The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula Iwherein:Q is selected from the group consisting of-- may represent a bond;T is —C(O)— or —CH(CN)—; and—Y— is selected from the group consisting ofcompositions thereof and their use for treating HIV infection.
REFERENCES:
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6573262 (2003-06-01), Wallace et al.
patent: 2003/0069266 (2003-04-01), Wang et al.
patent: 2003/0207910 (2003-11-01), Wang et al.
patent: 2004/0110785 (2004-06-01), Wang et al.
patent: 2005/0075364 (2005-04-01), Yeung et al.
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 99/51224 (1999-10-01), None
patent: WO 00/00201 (2000-01-01), None
patent: WO 01/22954 (2001-04-01), None
patent: WO 02/10152 (2002-02-01), None
patent: WO 02/085301 (2002-10-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/092695 (2003-11-01), None
patent: WO 04/000210 (2003-12-01), None
patent: WO 2004/011425 (2004-02-01), None
patent: WO 2004/043337 (2004-05-01), None
http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/HIV—treatment, last accessed Apr. 19, 2010.
Borisy, et. al., Proceedings of the National Academy of Sciences of the United States of America, 100(13) 2003; 7977-7982.
M. Font, et al., “Indoles and Pyridazino[4,5-b]indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
M. Kato, et al., “New 5-HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives,” Chem. Pharm. Bull, 43(8), pp. 1351-1357, 1995.
V. Levacher, et al., “Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo[2,3-b]Pyridine Derivatives,”Tetrahedron, 47(3), pp. 429-440, 1991.
E.V. Resnyanskaya, et al., “A Simple Synthesis of 1-Acyl-3-Aryl-3HPyrrolo[2′,3′:4,5]Pyrimido[6,1-b]Benzothiazol-6-ium-2-olates: Betainic Derivatives of a Novel Heterocyclic System,” Synthesis, 18, pp. 2717-2724, 2002.
P. Dan Cook, et al., “Pyrrolopyridazines. 1. Synthesis and Reactivity of Pyrrolo[2,3-d]Pyridazine 5-Oxides,” J. Het. Chem., 10(4), pp. 551-557, 1973.
Bender John A.
Kadow John F.
Meanwell Nicholas A.
Yang Zhong
Bristol--Myers Squibb Company
Jarrell Noble
Levis John F.
LandOfFree
Diazaindole-dicarbonyl-piperazinyl antiviral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diazaindole-dicarbonyl-piperazinyl antiviral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diazaindole-dicarbonyl-piperazinyl antiviral agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689376